A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Inflammatory or Non-Inflammatory Breast Cancer
The Study Treatment:
Radiation therapy and capecitabine are both designed to interfere with the growth of cancer
If you are found to be eligible to take part in this study, you will receive radiation
therapy once or twice a day, 5 days a week, for about 5 -7 weeks. The schedule and number
of weeks will be the doctor's decision based on the type of breast cancer.
The radiation treatments will take about 15-30 minutes each time.
You will take the Capecitabine pills by mouth every day during the 5-7 weeks that you
receive radiation therapy. The pills should be taken 2 times a day, about 12 hours apart,
30 minutes after eating food. On the radiation therapy days, you will take capecitabine
about 2 hours before the radiation therapy.
You will be given a pill diary in which you should record what time you take each dose of
Once a week while you are receiving study treatment, you will have a physical exam.
Length of Study:
You may remain on study treatment for up to 7 weeks. You will be taken off study treatment
early if the disease gets worse or intolerable side effects occur.
Based on the status of the cancer, if you become eligible to have surgery after radiation,
you will be referred to a surgeon to discuss that option.
At Month 3 after finishing radiation therapy (or surgery, if applicable), you will have a
positron emission tomography / computed tomography (PET/CT) scan or ultrasound to check the
status of the disease.
At Months 9, 17, and 29 after finishing radiation therapy or surgery, you may have a PET/CT
scan, ultrasound, and/or routine blood tests if your doctor thinks it is needed. The amount
of blood drawn, if any, will be the doctor's decision based on routine care.
This is an investigational study. Capecitabine is commercially available and FDA approved
to treat breast cancer that has spread. Radiation therapy is also commonly used to treat
breast cancer. The combination of capecitabine and radiation therapy is commonly used to
treat rectal cancer.
At this time, it is considered investigational to give the combination of capecitabine and
radiation therapy to patients with breast cancer.
Up to 60 patients will take part in this study. All will be enrolled at M. D. Anderson.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor Response (complete response + partial response) as measured by RECIST criteria
Assessed 4 weeks (+/- 4 days) after the last scheduled day of radiation
Wendy Woodward, MD, PHD
UT MD Anderson Cancer Center
United States: Institutional Review Board
|UT MD Anderson Cancer Center||Houston, Texas 77030|